The DOI matches its Crossref record.
Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications
Abstract
Metabolomics is the newest “omics” science. It is a dynamic portrait of the metabolic status of living systems. Metabolomics has brought new insights on metabolic fluxes and a more comprehensive and holistic understanding of a cell's environment. This burgeoning field promises to be a potential tool to fill the gap between genotype and phenotype. As its preceding “omics” sciences (ie, genomics and proteomics), metabolomics' aim is to dredge information hidden in a sea of data. This technology permits simultaneous monitoring of many hundreds, or thousands, of macro- and small molecules, as well as functional monitoring of multiple pivotal cellular pathways. In addition, elucidation of cellular responses to molecular damage, including evolutionarily conserved inducible molecular defense systems, could be achieved with metabolomics and could lead to the discovery of new biomarkers of molecular responses to functional perturbations. If metabolomic information could be translated into diagnostic tests, it might have the potential to impact on clinical practice, and it might lead to the supplementation of traditional biomarkers of cellular integrity, cell and tissue homeostasis, and morphological alterations that result from cell damage or death. In this review the concept and characteristics of metabolomics are introduced. Main current applications of metabolomics in cancer research are reviewed, including its potential in the drug discovery field, and, last but not least, its potential impact in the field of monitoring response and toxicity to anticancer agents. In the last section, research projects ongoing at our institution and future challenges for metabolomics will be presented and briefly discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 557
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T. L., Homans, S. W., Kessler, H., Luchinat, C., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2606 · Cited by 414
Self-citationHigh‐Throughput Metabolomics by 1D NMR
Vignoli, A., Ghini, V., Meoni, G., Licari, C., Takis, P. G., Tenori, L., Turano, P., & Luchinat, C. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804736 · Cited by 365
Molecular imaging in oncology: Current impact and future directions
Rowe, S. P., & Pomper, M. G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21713 · Cited by 337
Bernini, P., Bertini, I., Luchinat, C., Nincheri, P., Staderini, S., & Turano, P. (2011) · Journal of Biomolecular NMR · doi:10.1007/s10858-011-9489-1 · Cited by 332
Self-citation
Metadata
- Authors
- Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Di Leo, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-07-01
- Volume
- 25
- Issue
- 19
- Pages
- 2840-2846
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2083340629
- Cited by
- 246
- References
- 0
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications. https://app.cochat.ai/papers/10.1200/jco.2006.09.7550
- The paper
- Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Di Leo, A. (2007). Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.7550
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.